X-linked Retinoschisis clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible males ages 6 years and up
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.
San Francisco, California and other locations